Drug · CHEMBL623
NEFAZODONE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. NEFAZODONE. Drugs and targets, record CHEMBL623. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL623
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets4
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| HTR2A | 5-hydroxytryptamine receptor 2A | Serotonin 2a (5-HT2a) receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/3356 |
| HTR2C | 5-hydroxytryptamine receptor 2C | Serotonin 2c (5-HT2c) receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/3358 |
| SLC6A2 | Sodium-dependent noradrenaline transporter | Norepinephrine transporter inhibitor | INHIBITOR | https://conductscience.org/library/genes/6530 |
| SLC6A4 | Sodium-dependent serotonin transporter | Serotonin transporter inhibitor | INHIBITOR | https://conductscience.org/library/genes/6532 |
Source ChEMBL
Diseases5
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| major depressive disorder | Approval | ATC and TTD | 4 | 1 | https://conductscience.org/library/drugs?q=MONDO_0002009 |
| depressive disorder | Approval | TTD, at withdrawal | 2 | 1 | https://conductscience.org/library/drugs?q=MONDO_0002050 |
| cocaine abuse | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0004456 |
| cocaine dependence | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005186 |
| cocaine use disorder | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_0010445 |
Source Open Targets
Trials5
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00249509 | Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals | Phase 2 | 132 | nefazodone | Its name | ClinicalTrials.gov | |
| NCT00015210 | Nefazodone in the Treatment of Cocaine Dependence and Depression - 4 | Phase 2 | 69 | nefazodone | Its name | ClinicalTrials.gov | |
| NCT00231348 | Nefazodone in the Treatment of Social Phobia | Phase 4 | 24 | nefazodone | Its name | ClinicalTrials.gov | |
| NCT00000286 | Effects of Nefazodone on Treatment of Female Cocaine Abusers - 3 | Phase 2 | 0 | nefazodone | Its name | ClinicalTrials.gov | |
| NCT00000293 | Effect of Nefazodone on Relapse in Females With Cocaine Abuse - 10 | Phase 3 | 0 | nefazodone | Its name | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
None in this release.
Papers from its trials0
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
None in this release.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL623
GET https://conductscience.org/api/drugs/v1/CHEMBL623/targets